<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597268</url>
  </required_header>
  <id_info>
    <org_study_id>AP2007-50110</org_study_id>
    <nct_id>NCT04597268</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Ketamine Versus Midazolam in Endoscopic Procedures</brief_title>
  <official_title>Safety and Efficacy of Dexmedetomidine vs Ketamine vs Midazolam Combined With Propofol in Gastrointestinal Procedures for Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the safety and efficacy of dexmedetomidine versus ketamine versus&#xD;
      midazolam combined with propofol in cancer patients undergoing gastrointestinal endoscopic&#xD;
      procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison between using intravenous (IV) propofol combined with either IV dexmedetomidine or&#xD;
      IV ketamine or IV midazolam; to study the effect of their combination on level of sedation&#xD;
      and hemodynamic stability on adult patients scheduled for gastrointestinal endoscopic&#xD;
      procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ramsy sedation score (RSS)</measure>
    <time_frame>3 to 6 months</time_frame>
    <description>time to achievement of Ramsy sedation score (RSS) 3-4, Ramsy sedation scale score from 1 to 6, 1 meaning anxious and 6 meaning no response to stimulus</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Sedation and Analgesia</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>intravenous dexmedetomidine 1 mic/kg</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>propofol- dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine 1mg/kg</description>
    <arm_group_label>ketamine</arm_group_label>
    <other_name>propofol- ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>midazolam 0.05 mg/kg</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>propofol- midazolam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients scheduled for gastrointestinal endoscopic procedures&#xD;
&#xD;
          -  â‰¥ Age 18 years&#xD;
&#xD;
          -  ASA I-II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to any of the used drugs&#xD;
&#xD;
          -  impaired renal or liver functions&#xD;
&#xD;
          -  hypertensive patients&#xD;
&#xD;
          -  patients with cardiovascular&#xD;
&#xD;
          -  cerebrovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nahla Y Shehab, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <phone>01007798466</phone>
    <phone_ext>002</phone_ext>
    <email>walaa.elsabeeny@nci.cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nahla N Shehab, MD</last_name>
    <phone>01221682808</phone>
    <phone_ext>002</phone_ext>
    <email>nahla.shehab2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Walaa Y Elsabeeny</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walaa Y Elsabeeny, MD</last_name>
      <phone>01007798466</phone>
      <phone_ext>002</phone_ext>
      <email>Walaa.elsabeeny@nci.cu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla N Shehab, MD</last_name>
      <phone>01221682808</phone>
      <phone_ext>002</phone_ext>
      <email>Nahla.shehab2@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Walaa Youssef Elsabeeny</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and pain management</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data available upon reasonable request through contacting the corresponding author</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

